Form 4: Bausch Health GC Seana Carson Reports Share Dispositions

Bausch Health Companies Inc.'s EVP and General Counsel, Seana Carson, reported multiple dispositions of common shares and performance share units, including sales under a 10b5-1 plan and tax withholdings.

Summary

• Seana Carson, EVP and General Counsel of Bausch Health Companies Inc. (BHC), reported several transactions involving the company's common shares and performance share units.
• On February 27, 2026, 26,326 common shares were withheld to satisfy tax obligations upon the vesting of Restricted Share Units at a price of $5.93 per share.
• On March 2, 2026, 6,856 common shares were sold in the open market at $5.78 per share, executed under a Rule 10b5-1 plan adopted on May 7, 2025.
• Also on March 2, 2026, an additional 16,973 common shares were withheld for tax obligations related to Restricted Share Units vesting, at a price of $5.95 per share.
• On March 2, 2026, 137,922 performance share unit awards, originally granted on March 2, 2023, and earned on February 9, 2026, were disposed of in cash at $5.95 per unit, following a decision by the Talent and Compensation Committee to pay these awards in cash rather than common stock.
• On March 3, 2026, 4,420 common shares were sold in the open market at $5.77 per share, also under the Rule 10b5-1 plan adopted on May 7, 2025.
• Following these transactions, Seana Carson beneficially owns 616,761 common shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting routine insider transactions related to executive compensation and pre-planned stock sales, without indicating any significant positive or negative operational or strategic developments for Bausch Health Companies Inc.

Positives

• The disposition of performance share units in cash, rather than stock, could be seen as a positive for the company's share count, preventing dilution from the issuance of new shares.
• The sales of common stock were conducted under a pre-arranged Rule 10b5-1 plan, indicating planned liquidity rather than a reactive sale.

Negatives

• The aggregate disposition of 170,077 common shares and performance share units by a key executive could be interpreted as a reduction in insider ownership, potentially signaling a lack of confidence, although sales under 10b5-1 plans are often for personal financial planning.
• The sales occurred at prices ranging from $5.77 to $5.78, which are below the price of shares withheld for tax obligations ($5.93 and $5.95).

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports past insider transactions.

Management Comments

• The disposition in cash as contemplated by paragraph 7(1)(b) of the Income Tax Act (Canada) of 137,922 performance share unit awards originally granted to the Reporting Person under the Bausch Health Companies, Inc. 2014 Omnibus Incentive Plan on March 2, 2023, which, as previously reported on February 11, 2026, were earned, on February 9, 2026, upon certification by the Talent and Compensation Committee (the 'Committee') of the Board of Directors of the Issuer of the level of achievement of the applicable performance metrics, but remained subject to service-based vesting.
• As disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 2, 2026, the Committee subsequently took action to provide for the payment of such earned performance share unit awards in cash rather than Issuer common stock upon vesting.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales under pre-arranged 10b5-1 plans, are a common practice for executives to manage personal finances and diversify holdings. While the aggregate sales represent a reduction in direct insider ownership, the pre-planned nature often mitigates concerns about immediate negative sentiment, distinguishing it from opportunistic selling.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Rule 10b5-1 plans for executive stock sales is a standard practice across industries, including pharmaceuticals and healthcare, for managing insider trading compliance and providing liquidity.
• The decision by the Talent and Compensation Committee to pay performance share units in cash rather than stock is also a common mechanism to manage equity compensation and potential dilution, aligning with practices seen in companies like Pfizer or Johnson & Johnson when managing large executive compensation payouts.

Corporate Governance

Related Party Transactions

• The filing details the disposition of common shares and performance share units by Seana Carson, EVP and General Counsel of Bausch Health Companies Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The disposition of shares, particularly the sales under a 10b5-1 plan, represents a reduction in direct insider ownership. The cash payment for performance share units avoids potential dilution from new share issuance.
• Employees: The filing details the compensation structure for a key executive, specifically the vesting and payment of restricted and performance share units.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including tax withholdings and pre-planned sales under a 10b5-1 plan, as well as a cash settlement of performance share units. These transactions are generally expected for executives managing their compensation and personal finances and do not provide new information that would significantly alter the fundamental outlook or valuation of Bausch Health Companies Inc. Therefore, a 'hold' recommendation is appropriate as the filing does not present a compelling reason to buy or sell based solely on these disclosures.

Keywords

Bausch Health Companies Inc., BHC, Form 4, insider trading, Seana Carson, EVP General Counsel, stock sales, Rule 10b5-1 plan, restricted share units, performance share units, tax withholding, beneficial ownership